-$0.11 Earnings Per Share Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter

Equities research analysts expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to announce earnings per share of ($0.11) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for ZIOPHARM Oncology’s earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.08). ZIOPHARM Oncology posted earnings of ($0.13) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.4%. The business is scheduled to report its next quarterly earnings results on Thursday, March 7th.

On average, analysts expect that ZIOPHARM Oncology will report full-year earnings of ($0.52) per share for the current financial year, with EPS estimates ranging from ($0.55) to ($0.49). For the next year, analysts anticipate that the company will report earnings of ($0.32) per share, with EPS estimates ranging from ($0.36) to ($0.26). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for ZIOPHARM Oncology.

A number of research analysts have weighed in on ZIOP shares. BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 17th. Raymond James raised ZIOPHARM Oncology from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Thursday, November 15th. Finally, HC Wainwright set a $6.00 target price on ZIOPHARM Oncology and gave the stock a “buy” rating in a research report on Tuesday, November 13th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. ZIOPHARM Oncology has a consensus rating of “Hold” and an average price target of $5.33.

A number of institutional investors have recently modified their holdings of ZIOP. Jane Street Group LLC acquired a new stake in ZIOPHARM Oncology in the 3rd quarter worth about $161,000. Raymond James & Associates increased its holdings in ZIOPHARM Oncology by 168.3% in the 2nd quarter. Raymond James & Associates now owns 58,290 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 36,568 shares during the period. MetLife Investment Advisors LLC increased its holdings in ZIOPHARM Oncology by 77.1% in the 2nd quarter. MetLife Investment Advisors LLC now owns 65,990 shares of the biotechnology company’s stock valued at $199,000 after buying an additional 28,734 shares during the period. Belpointe Asset Management LLC bought a new position in ZIOPHARM Oncology in the 3rd quarter valued at about $262,000. Finally, Bank of America Corp DE increased its holdings in ZIOPHARM Oncology by 198.1% in the 2nd quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 201,063 shares during the period. Institutional investors and hedge funds own 39.95% of the company’s stock.

ZIOPHARM Oncology stock traded down $0.09 on Friday, hitting $3.33. 470,918 shares of the stock traded hands, compared to its average volume of 2,124,307. The firm has a market capitalization of $486.94 million, a P/E ratio of -6.28 and a beta of 1.85. ZIOPHARM Oncology has a 1 year low of $1.90 and a 1 year high of $5.24.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

See Also: Stock Symbols Definition, Examples, Lookup

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply